Design and rationale of a randomized control trial testing the effectiveness of combined therapy with STAtin plus FENOfibrate and statin alone in non-diabetic, combined dyslipidemia patients with non-intervened intermediate coronary artery disease - STAFENO study
- Authors
- Kwon, Taek-Geun; Jang, Albert Youngwoo; Kim, Sang Wook; Hong, Young Joon; Bae, Jang-Ho; Lee, Sung Yun; Kim, Sang-Hyun; Han, Seung Hwan
- Issue Date
- Apr-2020
- Publisher
- BMC
- Keywords
- Combination therapy; Fenofibrate; Randomized control trial; Residual cardiovascular risk; Statin; Virtual histology intravascular ultrasound
- Citation
- Trials, v.21, no.1, pp.353
- Journal Title
- Trials
- Volume
- 21
- Number
- 1
- Start Page
- 353
- URI
- https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/43545
- DOI
- 10.1186/s13063-020-04291-5
- ISSN
- 1745-6215
- Abstract
- BACKGROUND: Despite the chronicled success of low-density lipoprotein cholesterol (LDLc)-lowering statin therapy, substantial residual cardiovascular (CV) disease risk remains a problem worldwide, highlighting the need to for combination therapies targeting non-LDLc factors, such as with fenofibrate. METHODS/DESIGN: The STAFENO trial is a prospective, randomized, open-label, multi-center trial to compare the effect of statin plus fenofibrate with statin alone on the reduction and stabilization of plaque in non-diabetic, combined dyslipidemia patients with non-intervened, intermediate coronary artery disease (CAD) using virtual histology-intravascular ultrasound at 12 months. A total of 106 eligible patients are planned to be randomized to receive either a combination therapy (rosuvastatin 10 mg plus fenofibrate 160 mg/day) or monotherapy (rosuvastatin 10 mg/day) for 12 months. The primary endpoint of this study is the percentage change in the necrotic core volume. Secondary endpoints include changes in tissue characteristics and 1-year major CV events, including all-cause mortality, CV mortality, nonfatal myocardial infarction, stroke, and revascularization of the intervened and non-intervened lesions. DISCUSSION: The STAFENO trial will address whether combination treatment of statin and fenofibrate has an additive beneficial effect compared to statin alone on the reduction and stabilization of plaque and CV events in non-diabetic, combined dyslipidemia patients with non-intervened intermediate CAD. TRIAL REGISTRATION: ClinicalTrials.gov, NCT02232360. Registered 9 February 2014. https://register.clinicaltrials.gov/prs/app/action/SelectProtocol?sid=S0004ULE&selectaction=Edit&uid=U00023SZ&ts=2&cx=juppd2.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - 의과대학 > 의학과 > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/43545)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.